Introduction {#s1}
============

Voltage-gated ion channels are transmembrane proteins that are selectively permeable to physiological important ions such as Na^+^, K^+^, Ca^2+^, and Cl^-^. Under influence of the membrane potential (Vm) these channels change their conductance. In the conductive open (or activated) state, ions flow down their electrochemical gradient through the channel pore. The flux of these ions elicits an electrical current that directly influences the Vm. For voltage-gated sodium and potassium channels (Na~v~ and K~v~), the main focus of this review, the Vm will shift towards the ion\'s equilibrium potential, which under normal conditions is depolarizing and repolarizing, respectively ([@B50]). Although Na~v~ and K~v~ channels differ in selectivity from one another, their structure is quite similar. However, a main difference is that Na~v~ channels are characterized by one large α-subunit containing four recognizable domains (DI--IV), whereas K~v~ channels are formed by tetramerization of four individual α-subunits. In both cases, these four entities comprise six transmembrane segments (S1--S6), which are divided into a voltage sensing domain (VSD, S1--S4) and a pore-forming domain (PD, S5--S6) that are connected by the S4--S5 linker. The four PDs assemble into the ion permeation pathway (or pore) that is surrounded by four VSDs. In the non-conductive closed (or deactivated) state, ion permeation is prevented by the intracellular activation gate, located at the point where the four S6 helices cross. The aperture-like opening and closure of this gate is controlled by the VSD ([@B34]; [@B13]; [@B69]; [@B75]). The main component of the VSD is the S4 segment that physically moves in response to a change in Vm, due to the presence of positively charged residues (arginine and lysine) that detect changes in the membrane electric field ([@B17]). The S4--S5 linker is a component of the electro-mechanical coupling that translates S4 movements into opening or closing of the activation gate ([@B17]; [@B19]). After opening, fast inactivation occurs in Na~v~ and in some K~v~ channels, which is caused by the physical occlusion of the pore by an inactivation particle. For Na~v~ channels this inactivation particle is the linker between DIII and DIV, while in K~v~ channels it is located at the N-terminus of each subunit, hence termed N-type inactivation ([@B52]; [@B141]; [@B4]). Alternatively, K~v~ channel inactivation can occur *via* the slower C- or U-type inactivation mechanism that makes the channels non or less conductive ([@B53]; [@B65]; [@B29]).

Binding of drugs/toxins to Na~v~ and K~v~ channels may alter the activation, deactivation, and/or inactivation process(es), which may cause or alleviate aberrant electrical excitability. Therefore, knowledge about the different binding sites is key for drug development and pharmacovigilance. The binding sites for these drugs/toxins are well defined and categorized within the Na~v~ channel family, as opposed to the much larger K~v~ channel family. Most binding sites are enveloped by water, locating either inside or outside the channel\'s pore. However, some compounds bind to a site(s) that does not fit any of the hydrophilic binding sites. For instance, brevetoxins and ciguatoxins bind to a conserved hydrophobic site within the Na~v~ channel family, termed neurotoxin site 5 ([@B25]; [@B27]). For the K~v~ channel family no such site has been described, but certain compounds have been shown to deviate from binding to hydrophilic binding sites like; retigabine, gambierol, psora-4, polyunsaturated fatty acids (PUFAs), ICA-compounds ([@B128]; [@B67]; [@B70]; [@B21]). It is notable that these are rather lipophilic compounds and there has been, and still is, a growing interest in such compounds for their use in treating neurological disorders (e.g., as anti-convulsant).

So, is there a unifying picture of the lipid exposed/accessible drug/toxin binding sites within the large K~v~ channel family and even between K~v~ and Na~v~ channels? Several lipophilic binding sites have been described in different K~v~ channels, while in fact some may converge to just one binding region preserved between Kv channel (sub)families. In this review, the well-documented Na~v~ lipophilic binding sites, neurotoxin site 2, site 5, and the access to the local anaesthetic (LA) binding site within the pore through fenestrations is compared to what has been reported for K~v~ channels.

Voltage-Gated Sodium Channels {#s2}
=============================

The Na~v~ channel family contains nine isoforms (Na~v~1.1 to Na~v~1.9) that display a high sequence homology, especially within the transmembrane segments ([@B86]; [@B1]). This facilitated the categorization of drug/toxin binding sites within the Na~v~ channel family. Over the past decades a detailed picture emerged on where compounds bind within these channels and resulted in a well-documented classification of seven different sites (site 1 to 7) and a LA binding site ([@B115]; [@B32]). As the focus of this review is on the binding sites that involve lipid soluble and/or transmembrane binding compounds only binding site 5 and site 2 will be briefly discussed. The LA binding site is also mentioned as some compounds can reach their binding site *via* hydrophobic fenestrations in the pore wall of the channel protein. To maintain an orderly overview, all Na~v~ residues are numbered according to the Na~v~1.4 channel when possible. In case the sequence could not be aligned, as for bacterial Na~v~ structures, it will be noted and the original numbering is maintained.

The Closed State Accessible LA Binding Site: Pore-Accessibility Through Channel Fenestrations {#s2_1}
---------------------------------------------------------------------------------------------

LA compounds and anti-arrhythmic drugs inhibit Na~v~ channels by occlusion of the pore. Most LA compounds have a similar structure consisting of a tertiary hydrophilic amine domain (head) linked with an aromatic hydrophobic ring domain, with a total length of 10--15Å ([@B28]). Three types of block can be observed. First type is the use dependent open state block, or high affinity block, which occurs after channel opening and LA compounds enter the pore *via* the intracellular side ([@B46]; [@B16]; [@B45]). The second type is flicker block, or fast block, which is only observed when the channel\'s inactivation process is modulated. For example, by other compounds such as batrachotoxin (BTX) (CAS No.:23509-16-2) that binds at site 2 ([@B23]; [@B125]; [@B150]). The third and least common type is the resting or hydrophilic block that establishes when the channel is closed. LA compounds are thought to enter the ion conductive pore and find their binding site trough fenestrations in the lipid exposed part of the PD ([@B41]). LA compounds are protonated but for crossing the cell membrane they need to be deprotonated. This is possible when their pKA value is close to the physiological pH values in the extracellular environment. After traversing the cell membrane the compounds are protonated again to exert their pharmacological effect ([@B49]). As the binding site is located within the pore, block occurs with the highest affinity when the channel is opened or used, while applying frequent channel activating stimuli. Two residues within the S6 of domain four (DIV-S6) have been identified to be important for LA binding/modulation, namely, F1586 and Y1593, (Na~v~1.4 numbering). F1586 probably binds to the alkylamino head, while Y1593 interacts with the aromatic ring structure ([@B104]; [@B147]) ([**Figures 1A, B**](#f1){ref-type="fig"}). As these residues reside within the pore and certain compounds display closed state block, this requires a hydrophobic pathway to the binding site when the channel gate is closed ([@B49]).

![Representation of the local anaesthetic (LA) binding site and the hydrophobic access paths or fenestrations. **(A)** Schematic representation of the Na~v~ channel topology which contains four domains (DI to DIV) each consisting out of six transmembrane segments (S1--S6). Regions and location of residues important for LA binding are indicated with red arrows. Fenestrations that are sufficiently large to allow passage of LA compound are between DI--DII (fenestration 1) and DIII--DIV (fenestration 3) with the bottleneck residues listed below. This schematic representation is then followed by an alignment of Na~v~1.4 DIV with the other human isoforms, with marked in grey S6 and marked in red well conserved residues for LA binding and the fenestration bottleneck (I1582--I1583). Mutation of I1582 can also create a pathway connecting the inner pore with the extracellular environment. **(B)** 3D structure of the Na~v~1.4 channel representing the S5--S6 segments of DIII and DIV. In red are the residues, forming the LA binding site, visualized which are listed in panel A, clearly marking the inner pore LA binding site. **(C)** In the middle a top view of the 3D structure of the Na~v~1.4 channel is shown with in blue the DI--DII domains and in yellow the DIII-DIV domains. Fenestration 1 locates between DI and DII a side view of it shown on the left. A side view of fenestration 3 is shown on the right. Both fenestrations are highlighted by a red circle and the residues responsible for creating the bottleneck of the fenestration are represented in red. Below are the alignments of Na~v~1.4 with the other isoforms. On the left the bottleneck residue of DI is marked in red, on the right the bottleneck residues of DII. Amino acid sequence alignment and 3D structures are visualized using Jalview and chimera software, respectively ([@B102]; [@B139]).](fphar-11-00735-g001){#f1}

These pathways, or fenestrations, in the lipid exposed part of the PD were first observed in the crystal structure of bacterial Na~v~ channels such as Na~v~Ab ([@B99]; [@B100]), Na~v~Ms ([@B89]) and Na~v~Rh ([@B152]). It should be noted that bacterial Na~v~ channels are constructed out of four separate α-subunits instead of one large subunit. For the bacterial Na~v~ channels, four fenestrations are observed between the different domains where the radius of the fenestration varies from 0.8Å minimally to 2.59-2.83Å ([@B61]). Nonetheless, these fenestrations are wide enough for small LA compounds and anti-arrhythmic drugs to pass. The narrowest point in the fenestration, termed "bottleneck", is created by the amino acid residues M174, T175, F203, T206, and M209 (Na~v~Ab numbering), with F203 being the most important residue ([**Figure 1C**](#f1){ref-type="fig"}). These amino acids will sterically hinder the passage of compounds through the fenestration. Mutation of F203 to an alanine increased the size of the fenestration allowing easier access of flecainide (CAS No.:54143-55-4, polar surface area=59.6Å) to its binding site within the pore, with as result an increased tonic, closed state, block ([@B41]). The mutation did not affect lidocaine block as this compound is smaller (polar surface area=32.3Å) and can easily traverse the wild type fenestration ([@B28]). The F203W mutation on the other hand reduces fenestration size and consequently the access of both lidocaine and flecainide is reduced, decreasing tonic block ([@B41]). Computational modelling using the Na~v~1.4 3D structure resulted in the observation of four fenestrations just as in bacterial Na~v~ channels, with the exception that the size of two out of the four fenestrations seemed inadequate for compound access, namely the fenestration constructed by DII--DIII and DIV--DI ([@B61]). Fenestrations in between DI-DII and DIII-DIV seemed sufficiently wide for compounds to cross ([**Figure 1C**](#f1){ref-type="fig"}). The bottleneck of these fenestrations is formed by residues N790, L438, and M786 for the fenestration between DI-DII and by I1582, I1583, and F1586 (if rotated) for the fenestration between DIII-DIV. These fenestrations lining residues, are well conserved in the different Na~v~ channel isoforms. Mutating DIV-S6 residue I1582 appeared to create an extra pore access pathway ([@B104]) and allowed the external blocker QX314 (CAS No.:24003-58-5, polar surface area: 29.1Å), which is a charged LA compound at physiological pH and therefore not able to traverse the membrane, to access the LA binding site when added in the extracellular environment ([@B119]).

Apart from LAs that have a distinct binding site, sevoflurane (CAS No.: 28523-86-6), an inhalational anaesthetic, has a more complex binding profile. Sevoflurane binding results in a decrease of the peak sodium current, a hyperpolarised shift in the voltage dependence of inactivation and a slowing of the recovery from inactivation ([@B51]; [@B97]). Within the bacterial sodium channel NaChBac, binding regions have been located at the pore region, selectivity filter, and the S4--S5 linker/S6 interface ([@B96]; [@B105]). MD simulations suggested that the binding of sevoflurane to the selectivity filter and the S4--S5 linker occurs mainly when the channel is in the activated/open state, while in the closed state the channel gate and the VSD are targeted ([@B11]). A state independent binding site is possibly the central cavity that is accessed by the fenestrations. Residues T220 and F227 (NavChBac numbering) are proposed to be responsible for sevoflurane binding in the central cavity, which are the homologue residues for LA binding in Nav1.4 (F1764, Y1771).

Binding Site 2 Compounds, Though Being Lipophilic, Bind to the Inner Pore {#s2_2}
-------------------------------------------------------------------------

Compounds binding at site 2 of the Na~v~ channel include batrachotoxin ([@B31]; [@B54]), grayanotoxin ([@B149]; [@B57]), CAS No.: 54781-61-2), and alkaloids from plant such as veratridine ([@B126]; [@B120]), CAS No.:71-62-5), aconitine and mesaconitine ([@B47]; [@B40]) (CAS No.: 302-27-2). All these compounds are lipid soluble and need to traverse the cell membrane before influencing the channel in a use-dependent manner, comparable to the action of LA compounds ([@B47]; [@B26]; [@B54]; [@B36]; [@B120]; [@B12]; [@B3]; [@B149]; [@B132]). Their effects can be a combination of: (1) a hyperpolarised shift of the voltage dependence of activation, (2) inhibition of the fast inactivation process, leading to persistent sodium currents, (3) decrease in ion conductance, and/or (4) decrease of the Na^+^ selectivity. The location of binding site 2 is thought to be at the S6 of all four domains and to overlap with the LA binding site or at least allosterically hinder LA binding.

To describe neurotoxin site 2 in more detail, we focus on the most potent site 2 toxin reported to date, batrachotoxin (BTX) a steroidal alkaloid indirectly produced by the South-American poison dart frogs of the genus *Phyllobates* ([@B31]). Binding of BTX is highly irreversible and only possible when the channel is in its activated open state ([@B54]; [@B36]). BTX shifts the voltage dependence of channel activation by approximately −40 mV toward more hyperpolarized potentials ([@B81]), reducing the channel\'s ion conductance and selectivity. BTX also reduces the affinity for LA, which is thought to be caused by non-competitive antagonism (i.e., allosteric effect) because of overlapping binding sites as BTX and LA share the binding residue F1586 ([@B81]). Residue mutations affecting BTX in Na~v~1.4 were first described in DI-S6 and DIV-S6: I439K, N440K, L443K, F1586K, and N1591K, respectively ([@B130]; [@B131]). Afterwards the DIII-S6 residues Ser1283 and leu1287 were identified ([@B134]) and finally DII-S6 residues N790 and L794 ([@B135]). All these residues line the inside of the pore ([**Figure 2**](#f2){ref-type="fig"}). Non-pore lining residues involved in BTX sensitivity locate at the putative hinge region of the channel gate, Gly1282 and Phe1284, respectively ([@B35]). While Phe1284 is important for the stabilisation of the ammonium group of BTX, Gly1282 is not a direct binding receptor for BTX and mutations of this residue affect binding allosterically by changing the channels gating properties. Modeling studies suggest that BTX binds to the pore but does not completely prevent ion conduction because of its "horseshoe-like" structure ([@B35]). Only upon mutation of DII-S6 N790 BTX becomes a full blocker ([@B136]).

![Location of binding site 2 within the Na~v~1.4 channel. **(A)** Schematic visualisation of the Na~v~ ion channel structure which is constructed out of four domains (DI to DIV) each consisting out of six transmembrane segments (S1--S6). The red arrows indicate the probable residues responsible for constructing the site 2 receptor, residues are noted in their Na~v~1.4 annotation. **(B)** The bottom view of a 3D structure of the Na~v~1.4 channel with in red marking the residues constructing the binding site 2. Only the S5--S6 segments of each domain is shown for a clear view on the inner pore binding site. Around the 3D structure are the alignments of the known human sodium channels with the Nav1.4 channel (SCN4A) as reference, all positioned at the corresponding domain of the 3D structure. Marked in red are the residues which are necessary for site 2 toxin binding. While some variability is observed between some isoform, most of the residues are well conserved. Amino acid sequence alignment and 3D structure are visualized using Jalview and chimera software, respectively ([@B102]; [@B139]).](fphar-11-00735-g002){#f2}

Binding Site 5 Locates Between DIS6 and DIVS5 {#s2_3}
---------------------------------------------

Some of the toxins that bind to site 5 of Na~v~ channels are brevetoxins ([@B24]; [@B103]) and ciguatoxins ([@B93]; [@B77]), both originate from marine dinoflagellates (*Gambierdiscus toxicus*) and are structurally comparable. Brevetoxins are produced by unarmoured marine dinoflagellates (e.g., Karenia brevis, Gymnodinium breve, or Ptychodiscus brevis). Ingestion of these toxins can lead to poisoning and death of marine animals and cause the disease neurotoxic shellfish poisoning in humans ([@B8]; [@B39]). Eleven different brevetoxins have been discovered today with brevetoxin A (PbTX1, CAS No.:98112-41-5) and brevetoxin B (PbTX2 and 3, CAS No.:79580-28-2 and 85079-48-7) being the most investigated ones. These toxins are about 30Å in length, 6Å in width, and 6Å high. They are composed of four recognizable parts: a lactone ring (the head) linked with a linker to a multiple carbon ring (the tail) ending in a rest-group ([@B80]). While the head is responsible for the effect, without the linker and the tail the toxin cannot modulate the channel as it allows the head region to reach its binding site ([@B106]). PbTX binds to the Na~v~ channel at the DI-S6, DIV-S5, and DIV-S6 segments ([@B123]; [@B124]; [@B66]). The region spans within DI-S6 from Ala418/Thr422 to Lys465/Lys477 and within DIV-S5 from Glu1510 to lys1557 with possible extension to Lys1565 ([**Figure 3**](#f3){ref-type="fig"}). The tail of the molecule will be situated at the S5--S6 extracellular loop while the head is able to reach, due to the long linker and tail region, the inactivation gate at the intracellular side of the channel ([@B123]; [@B124]). Interaction of the head with the inactivation gate reduces channel inactivation, leading to a persistent sodium current ([@B114]; [@B112]).

![Location of binding site 5 in Na~v~1.4. **(A)** Alignment of the rat brain IIa sodium channel (SCN2A) with the human Na~v~1.4 (SCN4A) as reference. Marked in red are the regions where brevetoxin could bind. **(B)** Schematic topology of the Na~v~1.4 channel with the residues of DIS6 and DIVS5 that form the binding site listed below. On the right a schematic representation of the PD (top view) with the ion permeation pore represented in black and the location of binding site 5 indicated by the red circle. **(C)** 3D structures of the Na~v~1.4 channel seen from the top (left) and side (center, between DIII and DIV) are represented with in red the regions which are, using radioactive labelling studies, probably the location for brevetoxin binding. In blue residues are shown which had an effect on brevetoxin binding. With for DI M424, V429, I430, G434 decreasing affinity and F436, Y437 increasing affinity when mutated to alanine. In case of DIV mutation of I1485, G1486, L1488, L1489 lead to decrease and L1491, V1492, G1500, Y1506 to increase of affinity when mutated (Nav1.4 numbering) ([@B66]). A cleft can be observed in between DIS6 and DIVS5, at the side view, where the toxin could bind. This cleft is also located around fenestration four of the ion channel. At the left the structure of brevetoxin with the head region (1) attached with a linker (2) to the tail structure (3). The structure is orientated as it would bind at the channel compared to the side view. Amino acid sequence alignment and 3D structures are visualized using Jalview and chimera software, respectively ([@B102]; [@B139]).](fphar-11-00735-g003){#f3}

Like brevetoxins, ciguatoxins (CTX) bind at site 5 and their effects are consequently similar. Ciguatoxins are classified based on their geographic origin, with P-CTX ([@B93]) and C-CTX ([@B77]) standing for Pacific and Caribbean, respectively. In all Na~v~ channel isoforms P-CTX1 (CAS No.:11050 21 8), the most potent CTX discovered to date, induces a hyperpolarizing shift in the voltage dependence of channel activation ([@B18]; [@B14]; [@B117]) concomitantly with a shift in the voltage dependence of inactivation in some ([@B55]). As CTX and brevetoxin share the same binding site, they are logically going into competition with each other ([@B82]). Gambierol (CAS No.: 146763-62-4, origin *Gambierdiscus Toxicus*) has a similar structure as brevetoxins and CTXs, being a lipophilic multi-ring polyether toxin, but has no effect on the sodium currents ([@B76]). However, when administered simultaneously it decreases the effect of CTX and brevetoxin, suggesting that gambierol acts as a competitive antagonist that binds to site 5 or at least exerts a negative allosteric effect.

Voltage-Gated Potassium Channels {#s3}
================================

The K~v~ channel family is impressively large compared to this of Na~v~ channels, due to an extensive library of genes encoding different α-subunits that in some subfamilies can "mix-and-match" to form functional K~v~ channels. Additionally, alternative splicing, RNA editing, and post-translational modification further expand on the K~v~ channel family ([@B56]). This explains why the binding sites of the much larger K~v~ channel family are less well categorized than those of the Na~v~ channel family. The next part will highlight different binding sites and pore wall fenestrations within several, but not all, members of the K~v~ channel family. After a short overview of the well-documented extracellular and intracellular exposed "hydrophilic" binding sites, we will discuss in detail the lesser-known lipid embedded "hydrophobic" binding site(s) in different K~v~ channels.

Extracellular and Intracellular Exposed "Hydrophilic" Binding Sites {#s3_1}
-------------------------------------------------------------------

The well-documented K~v~ channel binding sites can be topologically located on the intracellular or extracellular side of the channels. Extracellularly the most well-known conserved binding sites are those of the pore blockers and VSD targeting gating modifiers, while intracellularly the inner pore block is the most notable one ([@B144]). Certain toxins from a variety of venomous animals target the extracellular binding sites. For example, scorpion toxins like charybdotoxin (CTX, CAS No.: 95751-30-7) and agitoxin (AgTx, CAS No.: 168147-41-9) target the water enveloped extracellular mouth of K~v~ channels, thereby physically occluding the permeation pore ([@B37]; [@B9]). Other scorpion toxins, like ergotoxin (ErgTx1, CAS No.: 8006-25-5) and BeKm-1 (CAS No.: 524962-01-4), cause an incomplete block of K~v~ current. This is because they only partially occlude the permeation pathway, which is known as "turret-block" ([@B146]; [@B151]; [@B48]). Gating modifier toxins, like tarantula toxins (Hanatoxin, SGTx1, and VSTx1), bind to the paddle motif (S3b helices, S3--S4 linkers, and S4 helices) at the extracellular protein-lipid interface of the VSD. This binding site cannot be characterized as strictly hydrophilic as the hydrophobic residues of these amphipathic peptide toxins allow it to partially partition into the membrane, and interact with the VSD ([@B72]; [@B59]; [@B2]; [@B121]; [@B60]; [@B91]). Intracellularly, compounds can bind in the inner cavity, either physically blocking ion permeation (e.g., quaternary ammonium ions) or allosterically modulating the gating machinery of K~v~ channels (e.g., 4-aminopyridine, CAS No.: 504-24-5) ([@B6]; [@B5]; [@B33]). Also, the quaternary ammonium ion TEA can occlude the external K~v~ pore, similar to the scorpion toxins mentioned above ([@B84]). Apart from the gating modifier binding site, which is partially enveloped by water, the binding sites mentioned here are exposed to an aqueous environment. Hence, referring them here as "hydrophilic" binding sites.

Lipid Embedded "Hydrophobic" Binding Site(s) and Pore Wall Fenestrations in the *Shaker*-Type K~v~ Family, K~v~7 Family, and K~v~10.1/K~v~11.1 Channel {#s3_2}
------------------------------------------------------------------------------------------------------------------------------------------------------

The next part reviews the potential lipophilic binding sites and pore wall fenestrations in different K~v~ channel types. To define the binding site(s) of certain compounds, the PD is divided into a "front side" and "back side". Residues of the front side point towards the VSD of the same α-subunit, while residues of the "back side" point in the opposite direction, thus towards the VSD of a neighboring α-subunit ([**Figures 4D**](#f4){ref-type="fig"}, [**5D**](#f5){ref-type="fig"} and [**6C**](#f6){ref-type="fig"}).

![Lipid-exposed binding sites within the crystal structure of a K~v~1.2--K~v~2.1 paddle chimera channel (PDB: 2R9R). **(A)** Sequence alignment of part of the PD (S5-S6 segment) of K~v~1.2-2.1, K~v~1.2, K~v~1.5, and K~v~3.1, with K~v~1.2-2.1 as reference. Residues important for gambierol and psora-4 action are highlighted in blue and yellow respectively. **(B)** Sequence alignment of the S3--S4 segments of K~v~1.2--2.1 and *shaker*, with K~v~1.2--2.1 as reference. Highlighted in green are the residues important for PUFA action. **(C)** Schematic visualization of one K~v~ channel α-subunit consisting out of six transmembrane segments (1--6) and a pore helix (PH). In blue the residues important for gambierol binding (L327, F330, and T397 according to Kv1.2--2.1 numbering) and in yellow those for psora-4 binding (L327, F329, F330, I333, L337, F338, I392, T397, and L400). Residues important for PUFA interaction are shown in green (V268, R287, V288, and L272). **(D)** Schematic visualization of the pore domain of the K~v~1.2--K~v~2.1 channel. Four pore-forming domains tetramerize to form the channel pore. The blue and yellow circle highlights the proposed gambierol/psora-4 binding site regions on the front- and/or backside of the pore-forming domain, respectively. **(E)** Side view of the K~v~1.2--K~v~2.1 channel with the front and back subunit omitted for clarity. Residues involved in gambierol and psora-4 interaction are shown in blue (L327, F330, and T397) and yellow (I392, T397, and L400), respectively. The PUFA action site is visualized in green (V268, R287, V288, and L272). **(F)** Top view of the K~v~1.2--K~v~2.1 channel, with each α subunit named α1--α4. Residues involved in gambierol and psora-4 interaction are shown in blue (L327, F330, and T397) and yellow (I392, T397, and L400), respectively. In green the PUFA action site comprising residuesV268, R287, V288, and L272. K~v~1.2--K~v~2.1 crystal structure (PDB: 2R9R) ([@B83]) was visualized with chimera software ([@B102]) and amino acid sequence alignment with Jalview ([@B139]).](fphar-11-00735-g004){#f4}

![Lipid-exposed binding sites within a homology model of the K~v~7.2 channel based on the 3D structure of K~v~7.1 (PDB: 5VMS). **(A)** Sequence alignment of part of the PD of K~v~7.1--K~v~7.5, with K~v~7.2 residue numbering. Highlighted in red and purple are the residues important for RTG and zinc pyrithione action, respectively. **(B)** Sequence alignment of the S3-S4 segment of K~v~7.2, K~v~7.4, and K~v~7.5, with K~v~7.2 as reference. Highlighted in green is the residue important for ICA73 action. **(C)** Schematic visualization of one K~v~7 channel α-subunit consisting out of 6 transmembrane segments (1--6) and a pore helix (PH). Location of the residues involved in the interaction of K~v~7.2 with retigabine are represented in red. Represented in purple are residues important for zinc pyrithione action). The residue important for ICA73 interaction is shown in green. **(D)** Schematic visualization of the PD of K~v~7.2. The red and purple circle highlight the proposed retigabine/zinc pyrithione binding site on either the front- or back-side of the PD pore-forming domain, respectively. **(E)** Side view of K~v~7.2 with the front and back subunit omitted for clarity. Residues involved in retigabine and zinc pyrithione interaction are shown in red (W236, L243, L299, and G301) and purple (L249 and L275), respectively. In green the ICA73 action site is visualized (A181). **(F)** Top view of K~v~7.2, with each α subunit named α1--α4. Residues important for retigabine, zinc pyrithione, and ICA73 action are shown in red (W236, L243, L299, and G301), purple (L249 and L275), and green (A181), respectively. Shown K~v~7.2 structure is a homology model of the 3D structure of K~v~7.1 (PDB: 5VMS) ([@B118]), generated with SWISS-MODEL ([@B140]) and visualized using chimera software ([@B102]). The amino acid sequences are aligned using Jalview ([@B139]).](fphar-11-00735-g005){#f5}

### The *Shaker*-Type K~v~ Channel Family {#s3_2_1}

Whereas gambierol does not modulate Nav channels, it is capable of inhibiting K~v~1 and K~v~3 channels ([@B94]; [@B30]; [@B67]). Gambierol\'s inhibitory mechanism has been extensively studied, whereby a threonine on S6, T427 in K~v~3.1, is an important determinant ([@B67]). Substitution of the polar threonine by a hydrophobic valine abolishes the high gambierol affinity ([@B67]). Additional determinants are a leucine and phenylalanine on S5: L348 and F351 in K~v~3.1, respectively. K~v~1 channels possess a threonine residue equivalent to T427 (T401 in K~v~1.2), explaining their similar gambierol sensitivity ([@B30]; [@B67]; [@B87]). These residues are mostly positioned on the front side of the PD ([**Figure 4**](#f4){ref-type="fig"}).

On the other hand, psora-4 (CAS No.: 724709-68-6), a potent inhibitor of K~v~1.3, has been shown to predominantly bind to the back side of the PD ([**Figure 4**](#f4){ref-type="fig"}) ([@B128]; [@B88]). A single psora-4 molecule acts as a central pore blocker of K~v~1 channels (K~v~1.1-K~v~1.5, and K~v~1.7), thereby preventing ions from permeating. However, four additional drug molecules can bind the lipid-exposed pocket on the back side of the PD, thereby causing the selectivity filter to narrow. Thus, the binding of five psora-4 molecules leads to a stable non-conducting state. The residues identified in K~v~1.5 as playing a key role in psora-4 action map on the back side of S5--S6 ([**Figure 4**](#f4){ref-type="fig"}). Additionally, some residues in S4 and the S4--S5 linker also seem involved ([@B88]).

The inhalation anaesthetic, sevoflurane, seems to bind within the central cavity and to a similar hydrophobic pocket as psora-4 ([@B116]). Apart from these binding regions, the polar lipophilic molecule has been shown to interact with the S4--S5 linker, pore helix, segment S6, and even the VSD, likewise to the many binding regions of sevoflurane on the Na~v~ channel ([@B10]; [@B11]). These sites are primarily dehydrated and lipid accessible, which is highly favourable for the polar lipophilic sevoflurane molecule ([@B116]). The specific residues involved in sevoflurane binding are not known, but one residue within the S4--S5 linker (G329 according to K~v~1.2 numbering) has been identified to play an important role ([@B78]).

PUFAs are charged lipophilic compounds that position at the lipid membrane interface, although in small quantities ([@B148]). Nonetheless, PUFAs may play an important role in the treatment of arrhythmias and epilepsy, due to their modulating effect on, but not limited to, voltage-gated ion channels ([@B74]; [@B71]; [@B20]; [@B21]). The *Shaker* K~v~ channel has been extensively studied as one of the targets of PUFAs. They interact with the channel at several sites, but the major one seems located within the lipid-facing cleft between S3 and S4 (S3--S4 cleft) of the VSD ([@B21]). This hydrophobic cleft is perfectly shaped to accommodate the lipophilic carbon tail of the PUFAs, causing the negatively charged carboxyl head group to be positioned close to the S4 segment. In this way, PUFAs electrostatically affect the VSD by trapping S4 toward the extracellular position, stabilizing the open state of *Shaker* K~v~ channels ([@B22]; [@B148]). Accordingly, a series of point mutations on the lipid facing side of S3-S4 (I325C, T329C, A359C, and I360C, *Shaker* numbering) had a significant impact on the PUFA-induced hyperpolarizing shift in the channel\'s voltage dependence of activation ([**Figure 4**](#f4){ref-type="fig"}) ([@B21]). Although the binding site for gating modifier toxins is in close proximity to that of PUFAs, the action sites do most likely not overlap as the residues important for PUFA action are more deeply embedded into the lipid bilayer ([@B21]). Interestingly, dehydroabietic acid (DHAA) and some of its derivatives, the most potent being Wu32and Wu122, have a similar effect on *Shaker* K~v~ channels. The carboxyl group of DHAA is positioned at roughly the same site, namely the S3--S4 cleft ([@B95]). Wu32 possibly interacts with residues between the S2--S3 and/or S3--S4 cleft as five cysteine mutations in S3, which have been shown to alter its affinity and/or efficacy, point towards S2 (I320C and F324C, *shaker* numbering) and S4 (I318C, P322C, and T326C), respectively ([@B95]).

### The K~v~7 Family {#s3_2_2}

The well characterized retigabine (RTG, CAS No.: 150812-12-7) binding site is localized between the front side of one PD and the back side of an adjacent PD of K~v~7.2--K~v~7.5 (KCNQ2-5) channels ([**Figure 5**](#f5){ref-type="fig"}) ([@B111]; [@B70]). These channels are predominantly expressed in neurons where they underlie the native M-current that plays a major role in regulating neuronal excitability ([@B133]; [@B68]; [@B113]). RTG amplifies the K~v~7.2--K~v~7.5 currents by stabilizing the open-channel conformation, by which it acts as a brake on neuronal excitability *in vivo* ([@B70]). Hence, the potential use of RTG and RTG-derived compounds as anticonvulsants ([@B107]; [@B138]). RTG binding has been attributed to several conserved residues on S5--S6, lining a hydrophobic pocket near the channel gate of K~v~7.2--K~v~7.5. According to K~v~7.2 numbering these residues are: W236, L243, L275, L299, and G301 ([**Figure 5**](#f5){ref-type="fig"}). K~v~7.1 channels lack these amino acids (apart from L243), explaining their RTG-insensitivity ([@B111]; [@B70]). Because of the role of K~v~7 in diseases of neuronal hyperexcitability, the search for positive allosteric modulators such as RTG, for which the clinical use is currently discontinued ([@B138]), is pursued. For example, BMS-204352, ML-213, and the acrylamide compound (S)-1 act on the canonical RTG binding site ([@B15]; [@B64]; [@B138]).

The hydrophobic pocket of the RTG binding site also seems to be able to accommodate endogenous hydrophilic neurotransmitters like γ-aminobutyric acid (GABA), which directly activates K~v~7.3 and K~v~7.5 *via* W236. In contrast to RTG, GABA does not readily cross the plasma membrane to reach its site of action. Based on the K~v~1.2--K~v~2.1 paddle chimera structure the tryptophan also seems to be accessible from the extracellular side ([@B85]). It is possible that this accessibility is dependent of the state of the channel, such that in certain conformations the mostly hydrophobic binding pocket can be reached by hydrophilic compounds like GABA. Additionally, not all K~v~7 channel openers interact with residue W236. Zinc pyrithione for instance interacts with two residues at the back side of S5 and the pore helix (L249 and L275) ([**Figure 5**](#f5){ref-type="fig"}) ([@B111]; [@B145]; [@B70]).

ICA-compounds (ICAgen, Durham, NC, US), which are benzanilide K~v~7 channel openers, were developed as RTG alternatives ([@B90]). Of these, the most well-documented is ICA-27243 (ICA43), which has been shown to be more selective than RTG ([@B142]). The individual residues that determine ICA43 binding have not been identified, but the C-terminal end of S2 and the N-terminal part of S3 (S2--S3 cleft) are proposed to be involved ([@B98]). Later, Wang AW, et al. continued the investigation of the mechanism of action of ICA-compounds on K~v~7 channels, but focussed on ICA-069673 (ICA73) ([@B137]). They identified two key residues in S3 of K~v~7.2: A181 and F168, respectively. Mutation of these residues did not affect RTG-mediated gating, but did alter the action of ICA73 ([@B137]). Furthermore, it has been shown that ICA43 and ICA73 are resistant to mutation of the RTG binding site, supporting that not all K~v~7 channel openers bind to the PD, but also can interact with a VSD site ([@B98]; [@B137]). However, it remains debated whether residues A181 and F168 are involved in ICA binding directly or allosterically ([@B138]). In case these residues are binding ICA73, the position of residue A181 toward the lipid-exposed surface of the VSD suggests the presence of a drug binding site at the lipid-exposed cleft of S2--S3 and/or S3--S4 in K~v~7 channels, similar to the interaction of Wu32 with *Shaker* K~v~ channels ([**Figure 5**](#f5){ref-type="fig"}).

PUFAs have also been described to electrostatically affect K~v~7.1 channels, resulting in a negative shift of the conductance-voltage curve. This modulation of K~v~7.1 channels by PUFAs is similar to what has been described for *shaker* K~v~ channels ([@B22]; [@B21]). Hence, the binding site and mechanism of action of PUFAs are most likely similar for both channels ([@B79]).

### The hERG (K~v~11.1) and EAG (K~v~10.1) Channel {#s3_2_3}

The human *ether-a-go-go* related gene (hERG) type 1 encodes for the K~v~11.1 channel, which functions as the rapid component of the delayed rectifier K^+^ current contributing to the repolarization of cardiac action potentials ([@B127]). Alteration of the native functioning of K~v~11.1 channels, either genetically or pharmacologically, can disrupt this repolarization, leading to various cardiac rhythm disorders ([@B122]). Furthermore, the role of K~v~11.1 is not limited to the heart, as it also seems to play a role in the central nervous system, digestive, secretory, and reproductive system, and even cancer ([@B7]). Hence, it has become common practice to screen compounds on hERG channel activity during the early stages of drug development, as unintentional side-effects may lead to disease and sudden-death ([@B92]; [@B122]; [@B7]). Most hERG inhibitors interact with residues inside the channel\'s permeation pathway, either located on the pore helix (T623,S624, and V625, according to hERG numbering) or on segment S6 (G648, Y652, and F656) ([@B73]; [@B92]; [@B62]; [@B108]; [@B109]; [@B38]; [@B63]). On the other hand, some small molecule hERG activators have been discovered who deviate from this binding site, like ICA-105574 (ICA74) and PD-118057 (PD57). The most critical binding determinants for ICA74 are F557 and L622 ([@B42]), which topologically would situate the binding site at the front side of the PD ([**Figure 6**](#f6){ref-type="fig"}). Apart from these critical binding determinants several other residues have been proposed to line the hydrophobic ICA binding pocket of K~v~11.1 (F619, T623, M645, L646, M651, Y652, and F656), situating the ICA74 binding site between the front side of one α-subunit and the back side of an adjacent α-subunit ([@B44]). PD57 seems to bind the same hydrophobic pocket, with key residues being L646 on segment S6 and F619 on the pore helix of an adjacent subunit ([**Figure 6**](#f6){ref-type="fig"}) ([@B101]).

![Lipid-exposed binding site(s) within the cryo-EM structure of the K~v~11.1 (hERG) channel (PDB: 5VA1). **(A)** Sequence alignment of part of the PD of K~v~11.1 and K~v~10.1, with K~v~11.1 residue numbering. Highlighted in pink and blue are the residues important for ICA74 and PD57 action, respectively. **(B)** Schematic visualization of one K~v~ channel α-subunit consisting out of six transmembrane segments (1--6) and a pore helix (PH). In blue the critical residues of PD57 (F619 and L646 according to Kv11.1 numbering) and in pink the residues lining the proposed hydrophobic ICA74 binding pocket (F619, F557, L622, T623, M645, L646, M651, Y652, and F656). **(C)** Schematic visualization of the pore domain of the K~v~11.1 channel. Four pore-forming domains tetramerize to form the channel pore. The blue and pink circle highlights the proposed PD57 and ICA74 binding site regions on the front- and/or backside of the pore-forming domain. **(D)** Side view of the K~v~11.1 channel with the front and back subunit omitted for clarity. Residues involved in PD57 and ICA74 interaction are shown in blue (F619 and L646) and pink (F619, F557, L622, T623, M645, L646, M651, Y652, and F656), respectively. The residues F619 and L646 are both critical residues for PD57 and ICA74, but are shown in blue. **(E)** Top view of the K~v~11.1 channel, with each α subunit named α1--α4. Residues involved in PD57 and ICA74 interaction are shown in blue (F619 and L646) and pink (F619, F557, L622, T623, M645, L646 M651, Y652, and F656), respectively. K~v~11.1 cryo-EM structure (PDB: 5VA1) ([@B129]) was visualized with chimera software ([@B102]) and amino acid sequence alignment with Jalview ([@B139]).](fphar-11-00735-g006){#f6}

Interestingly, ICA74 binds to a similar hydrophobic pocket in the related ether-a-go-go (EAG) type 1 channel (K~v~10.1), although eliciting an opposite effect as in K~v~11.1. ICA74 inhibits K~v~10.1 currents by enhancing channel inactivation ([@B43]). The key residues for ICA74 binding in K~v~11.1 (F557 and L622) are indeed conserved in K~v~10.1 (F359 and L434). Furthermore, only three residues (F619, L646, and M651) of the proposed ICA binding pocket in K~v~11.1 appeared not to be conserved in the K~v~10.1 channel. This strongly suggests that ICA74 binds to the same hydrophobic site in K~v~10.1 and K~v~11.1 channels ([@B44]).

### Lateral Pore Wall Fenestrations {#s3_2_4}

The reports of compounds that can access the inner cavity from lipid exposed side-pocket through lateral pore wall fenestrations in Kv channels is still very limited. In K~v~7.1 a pore wall fenestration is formed upon interaction with the β-subunit KCNE1 such that adamantane compounds, AC-1 (CAS No.: 878489-28-2) and its analogs (ACs), can reach their binding site ([@B58]; [@B143]). Interestingly, AC-1 does not affect currents generated by homomeric K~v~7.1, channels, nor K~v~7.1 co-expressed with other KCNE isoforms (KCNE2-5). Thus, the "β-subunit-induced fenestrations" seem to be required for AC binding. Within these fenestrations many residues have been identified as important for AC-1 activity (V334, F335, I337, F340, and A344, according K~v~7.1 numbering), but its position relative to the central cavity and lipophilic side-pocket could not be elucidated ([@B143]).

In K~v~11.1, a lateral pore wall fenestration is possibly formed upon mutation of residue F557 to leucine (F557L), explaining the decrease in current inhibition of six known hERG blockers (dofetilide, haloperidol, terfenadine, astemizole, cisapride, and amiodarone) ([@B110]). For K~v~1.5 it has been proposed that psora-4 molecules can move in the I502A mutant between the central cavity and the lipophilic side-pockets through fenestration between segments S5--S6 ([@B88]).Hence, the presence of pore wall fenestrations has thus far only been observed upon β-subunit interaction with K~v~7.1 and to be induced by mutations in K~v~1.5 and K~v~11.1 ([@B88]; [@B110]; [@B143]). Although the presence of fenestrations has not been reported yet for wild-type channels, the likelihood that some K~v~ channel types express lateral pore wall fenestrations increases. If present, these fenestrations may be similar to those characterized in Na~v~ channels, which allow LA\'s to pass between the central cavity and lipophilic side-pockets ([@B99]; [@B89]; [@B100]; [@B152]; [@B61]; [@B143]).

Unifying the Lipid Exposed/Accessible Drug/Toxin Binding Sites of K~v~ and Na~v~ Channels {#s4}
=========================================================================================

Whereas a classification exists for the different drug/toxin binding sites in Na~v~ channels, such a categorization is currently lacking for the Kv channel family. In this review we take a first step and describe the hydrophobic binding sites reported in different K~v~ channel families. A compound like gambierol ([**Figures 4**](#f4){ref-type="fig"} and [**7**](#f7){ref-type="fig"}) has been shown to mostly bind to the front side of the PD, while RTG ([**Figures 5**](#f5){ref-type="fig"} and [**7**](#f7){ref-type="fig"}) PD57, and ICA74 ([**Figure 6**](#f6){ref-type="fig"}) also interact with the back side of the PD of an adjacent α-subunit. When mapping all the sites it appears that gambierol, ICA74, RTG, and PD57 bind to an analogues binding site present in different K~v~ channel types ([**Figure 7**](#f7){ref-type="fig"}) ([@B111]; [@B67]; [@B70]; [@B101]; [@B42]; [@B87]). This indicates that an analogues lipophilic binding site is conserved between the different K~v~ channel types.

![Superposition of the lipid-exposed binding sites within the K~v~1.2--2.1 paddle chimera channel (PDB: 2R9R) and K~v~7.2. **(A)** Side view of one α-subunit of the K~v~1.2--2.1 channel with the residues important for gambierol, psora-4, and PUFA action represented by spheres and highlighted in blue, yellow, and green, respectively. The VSD, PD, and S4--S5 linker are also indicated. **(B)** Side view of one K~v~7.2 α-subunit with the residues important for retigabine, zinc pyrithione, and ICA73 action represented by red, purple, and green spheres, respectively. **(C)** Superposition of the structures shown in panel **(A, B)**. **(D)** Superposition of the K~v~1.2--2.1 and K~v~7.2 channel structure shown as top view. The red and blue circle highlight the proposed retigabine/gambierol binding site on the "front side" of the PD, while the binding sites for zinc pyrithione and psora-4 on the "back side" of the PD are highlighted with the purple and yellow circles, respectively. Structures are visualized using chimera software ([@B102]).](fphar-11-00735-g007){#f7}

Zinc pyrithione, on the other hand, seems to solely bind to the back side of the PD, implying that the front and back side of the PD could serve as distinct binding sites ([**Figures 5**](#f5){ref-type="fig"} and [**7**](#f7){ref-type="fig"}) ([@B145]). Psora-4 and sevoflurane are less specific regarding their binding site, as they both bind to the front and back side of the PD, among others ([@B88]; [@B78]; [@B116]). Although certain compounds solely bind to the front or back side of the PD it seems that all residues point toward a similar lipophilic region, leading to the speculation that these seemingly distinct binding sites may converge to just one conserved lipophilic binding region in K~v~ channels. This binding site is then most likely similar to neurotoxin site 5 in Na~v~ channels ([**Figure 3**](#f3){ref-type="fig"}) ([@B25]; [@B27]), located between DIS6-DIVS5 ([**Figures 3**](#f3){ref-type="fig"}, [**4**](#f3){ref-type="fig"}, [**5**](#f5){ref-type="fig"}) ([@B66]). The idea that these binding sites are orthologous equivalents is because gambierol presumably binds to site 5 in Na~v~ channels ([@B76]). In the case of K~v~ channels four such binding sites are present due to its tetrameric nature, as opposed to Na~v~ channels who only have one neurotoxin site 5 ([@B111]; [@B67]; [@B70]; [@B88]; [@B116]).

Another lipid facing binding site is located on the VSD, in particular the cleft between segments S2--S3 and S3--S4. PUFAs, DHAA and its derivatives, and ICA-compounds allegedly bind to these clefts in *Shaker* and K~v~7 channels, respectively ([**Figures 4D**](#f4){ref-type="fig"}, [**5D**](#f5){ref-type="fig"}, and [**7**](#f7){ref-type="fig"}) ([@B98]; [@B21]; [@B95]; [@B137]). This leads to the assumption that also this lipophilic binding site is conserved between different K~v~ channel types. Additionally, certain compounds of Na~v~ (LAs and sevoflurane) and K~v~ (AC-1, psora-4, and several hERG blockers) channels have been proposed to use hydrophobic lateral pore wall fenestrations to reach their binding sites. The location of these fenestrations in Na~v~ channels are situated between DI--DII and DIII--DIV ([**Figure 1**](#f1){ref-type="fig"}), while in K~v~ channels they are most likely present between segments S5--S6, allowing lipid soluble compounds to reach their binding site even when the channel is in its closed state ([@B99]; [@B89]; [@B100]; [@B152]; [@B88]; [@B11]; [@B61]; [@B110]; [@B143]).

Of note, the residues reported to affect drug/toxin affinity were in this review mapped on available 3D structures that are snapshots of the channel in a certain state, which should not be the high affinity state for the respective drug/toxin. As mentioned, several drugs/toxins are state dependent and bind with highest affinity to a certain conformation of the channel (e.g., the closed or open channel configuration). Consequently, the residues reported to be important for drug/toxin effect might orient differently when the conformation of the channel changes. Thus, when the channel is in its high affinity drug/toxin state, the orientation of the residues might be slightly different resulting in possibly broader binding regions than highlighted in the figures. Furthermore, several of the residues reported to be important for drug/toxin effect are likely not the binding partners of the drugs/toxins but alter affinity in an allosteric way. Nonetheless, there seem to be three distinct lipid-exposed binding sites preserved in K~v~ channels: the front and back side of the PD, and S2--S3/S3--S4 clefts. Future experiments will determine if the front and back PD binding sites are two distinct entities or if they converge to just one larger lipophilic binding site region.
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